May 31, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Daraxonrasib offers ‘transformational’ benefit in metastatic pancreatic cancer
CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based on the buzz it created among ASCO Annual Meeting attendees, the benefits observed with daraxonrasib among pretreated individuals with metastatic disease exceeded already-lofty expectations.
1,901 words~9 min read
